Servier Korea began supplying Oncaspar Lyophilized Inj, a combination treatment for "acute lymphocytic leukemia (ALL)" from the 10th. It was supplied through the rare drug center, but the license holder, Servier, was in charge of the supply, and insurance benefits have not yet been registered. Servier Korea is undergoing prescription procedures at major general hospitals to ensure that Rx for Oncaspar can continue smoothly as supplies to rare drug centers are exhausted. Acute Lymphoblastic Leukemia (ALL) treatment was approved by the MFDS as a rare specialty drug in February last year as a combination therapy with other anti-tumor drugs.

Oncaspar is a drug that maximizes the half-life of drug circulatio